STING antagonist/inhibitors

Other Immunology & Inflammation Inhibitors

• Featured Inhibitors
• Inhibitors (7)
• Agonists (13)
• Activator (1)
• Agonists (2)

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S8796	diABZI STING agonist-1 (tautomerism)	diABZI STING agonist (diABZI STING agonist-1, Compound 3, Tautomerism) is a potent non-nucleotide STING agonist and has tremendous potential to improve treatment of cancer in humans.Solutions are unstable and should be fresh-prepared.	Cell Discov, 2025, 11(1):23 Nat Biomed Eng, 2025, 10.1038/s41551-025-01400-0 J Exp Med, 2025, 222(5)e20241184
S6652	H-151	H-151 is a highly potent and covalent inhibitor of STING that has noteworthy inhibitory activity both in human cells and in vivo.	Clin Transl Med, 2025, 15(3):e70235 J Neuroinflammation, 2025, 22(1):14 Cell Death Dis, 2025, 16(1):641
S1537	Vadimezan (DMXAA)	Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. It is also a STING agonist with potential antineoplastic activity, potently inducing IFN-β but relatively low TNF-α expression in vitro. This compound has antiviral activity. Phase 3.	Cell Chem Biol, 2025, 32(2):280-290.e14 Commun Biol, 2025, 8(1):1470 Front Pharmacol, 2025, 16:1528459
S6575	C-176	STING inhibitor C-176 is a potent, small-molecule inhibitor of STING, a central signalling component of the intracellular DNA sensing pathway.	Nat Commun, 2025, 16(1):289 J Clin Invest, 2025, e193945 MedComm (2020), 2025, 6(10):e70411
S6667	STING inhibitor C-178	C-178 is a covalent inhibitor of STING, covalently binding to Cys91.	Nature, 2025, 647(8090):735-746 Neurosci Lett, 2025, 847:138095 Research Square, 2023, Version 2
S7904	2',3'-cGAMP Sodium Salt	2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium) is produced in response to DNA in the cytoplasm in mammalian cells and binds STING with high affinity and is an effective inducer of interferon-β (IFNβ). 2',3'-cGAMP binds to STING with Kd of 3.79 nM.	J Nanobiotechnology, 2025, 23(1):724 Cancer Sci, 2025, 10.1111/cas.70162 J Biol Chem, 2025, 301(10):110653
S0853	SR-717 lithium	SR-717 lithium is a non-nucleotide STING agonist that demonstrates broad interspecies and interallelic specificity with EC50 of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 (cGAS KO) cell lines, respectively. SR-717 lithium also induces the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner. SR-717 lithium exhibits antitumor activity.	Nat Commun, 2025, 16(1):3440 Pharmaceutics, 2024, 16(9)1216 Mol Neurobiol, 2022, 59(11):7006-7024
E1066	SN-011	SN-011 is a STING-specific inhibitor with an IC50 of 76 nM.	Mol Pharm, 2025, 10.1021/acs.molpharmaceut.4c01297 Mol Cancer, 2024, 23(1):186
S9681	MSA-2	MSA-2 is an orally available non-nucleotide human STING agonist with antitumor activity.	J Colloid Interface Sci, 2025, 686:1019-1032 Cell Discov, 2022, 8(1):133
E0128	C-171	C-171 is a covalent small-molecule inhibitor of STING. This compound efficiently inhibits both hsSTING and mmSTING through covalently targeting the predicted transmembrane cysteine residue 91 and thereby blocking the activation-induced palmitoylation of STING.	Cell Reports, 2023, 112328 Cell Rep, 2023, 42(4):112328
1 2